Early-onset pneumonia with multidrug-resistant organisms is a major concern for patients who have received a liver transplant, and pre- and intra-operative risk factors influence its development, according to study data presented at The American Association for the Study of Liver Diseases’ The Liver Meeting, held November 8 to 12, 2019 in Boston, Massachusetts. In an…
Managing the risk for infection is one of the primary tasks in optimizing outcomes for solid organ transplant recipients.
The epidemiology of acute gastroenteritis pathogens identified from pediatric patients who have undergone allogenic hematopoietic cell transplant may be changing.
Patients with recurrent Clostridioides difficile infection who receive treatment with fecal microbiota transplantation are less likely to develop a primary bloodstream infection.
Patients with established chronic lung allograft dysfunction may have a higher risk for respiratory syncytial virus infections, but lung function decline does not appear to be significantly affected.
Bloodstream infections are common in patients who have received a solid organ transplants.
HCV-viremic kidneys are increasingly being used for transplants and seem to have good one-year outcomes.
Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
Vaccination of solid organ transplant candidates and recipients remains a critical component of preventing infection related morbidity and mortality.
Treatment with DAAs before liver transplantation is associated with improved outcome and appears to be safe in patients with decompensated hepatitis C-related cirrhosis.
